Cargando…
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential
Prostate cancer (PCA) is a major health concern in current times. Ever since prostate specific antigen (PSA) was introduced in clinical practice almost three decades ago, the diagnosis and management of PCA have been revolutionized. With time, concerns arose as to the inherent shortcomings of this b...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437363/ https://www.ncbi.nlm.nih.gov/pubmed/26317031 http://dx.doi.org/10.1155/2014/321680 |
_version_ | 1782372198981304320 |
---|---|
author | Batra, Jaspreet Singh Girdhani, Swati Hlatky, Lynn |
author_facet | Batra, Jaspreet Singh Girdhani, Swati Hlatky, Lynn |
author_sort | Batra, Jaspreet Singh |
collection | PubMed |
description | Prostate cancer (PCA) is a major health concern in current times. Ever since prostate specific antigen (PSA) was introduced in clinical practice almost three decades ago, the diagnosis and management of PCA have been revolutionized. With time, concerns arose as to the inherent shortcomings of this biomarker and alternatives were actively sought. Over the past decade new PCA biomarkers have been identified in tissue, blood, urine, and other body fluids that offer improved specificity and supplement our knowledge of disease progression. This review focuses on superiority of circulating biomarkers over tissue biomarkers due to the advantages of being more readily accessible, minimally invasive (blood) or noninvasive (urine), accessible for sampling on regular intervals, and easily utilized for follow-up after surgery or other treatment modalities. Some of the circulating biomarkers like PCA3, IL-6, and TMPRSS2-ERG are now detectable by commercially available kits while others like microRNAs (miR-21, -221, -141) and exosomes hold potential to become available as multiplexed assays. In this paper, we will review some of these potential candidate circulating biomarkers that either individually or in combination, once validated with large-scale trials, may eventually get utilized clinically for improved diagnosis, risk stratification, and treatment. |
format | Online Article Text |
id | pubmed-4437363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-44373632015-08-27 A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential Batra, Jaspreet Singh Girdhani, Swati Hlatky, Lynn J Biomark Review Article Prostate cancer (PCA) is a major health concern in current times. Ever since prostate specific antigen (PSA) was introduced in clinical practice almost three decades ago, the diagnosis and management of PCA have been revolutionized. With time, concerns arose as to the inherent shortcomings of this biomarker and alternatives were actively sought. Over the past decade new PCA biomarkers have been identified in tissue, blood, urine, and other body fluids that offer improved specificity and supplement our knowledge of disease progression. This review focuses on superiority of circulating biomarkers over tissue biomarkers due to the advantages of being more readily accessible, minimally invasive (blood) or noninvasive (urine), accessible for sampling on regular intervals, and easily utilized for follow-up after surgery or other treatment modalities. Some of the circulating biomarkers like PCA3, IL-6, and TMPRSS2-ERG are now detectable by commercially available kits while others like microRNAs (miR-21, -221, -141) and exosomes hold potential to become available as multiplexed assays. In this paper, we will review some of these potential candidate circulating biomarkers that either individually or in combination, once validated with large-scale trials, may eventually get utilized clinically for improved diagnosis, risk stratification, and treatment. Hindawi Publishing Corporation 2014 2014-03-12 /pmc/articles/PMC4437363/ /pubmed/26317031 http://dx.doi.org/10.1155/2014/321680 Text en Copyright © 2014 Jaspreet Singh Batra et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Batra, Jaspreet Singh Girdhani, Swati Hlatky, Lynn A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
title | A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
title_full | A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
title_fullStr | A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
title_full_unstemmed | A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
title_short | A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
title_sort | quest to identify prostate cancer circulating biomarkers with a bench-to-bedside potential |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437363/ https://www.ncbi.nlm.nih.gov/pubmed/26317031 http://dx.doi.org/10.1155/2014/321680 |
work_keys_str_mv | AT batrajaspreetsingh aquesttoidentifyprostatecancercirculatingbiomarkerswithabenchtobedsidepotential AT girdhaniswati aquesttoidentifyprostatecancercirculatingbiomarkerswithabenchtobedsidepotential AT hlatkylynn aquesttoidentifyprostatecancercirculatingbiomarkerswithabenchtobedsidepotential AT batrajaspreetsingh questtoidentifyprostatecancercirculatingbiomarkerswithabenchtobedsidepotential AT girdhaniswati questtoidentifyprostatecancercirculatingbiomarkerswithabenchtobedsidepotential AT hlatkylynn questtoidentifyprostatecancercirculatingbiomarkerswithabenchtobedsidepotential |